Safety and Effectiveness of Two Doses of ABT-874 as Compared to Placebo in Subjects With Multiple Sclerosis (MS)

NCT ID: NCT00086671

Last Updated: 2013-01-04

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 215 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2004-04-30
• Study Completion Date: 2006-11-30

Brief Summary

The objective of the trial is to study the safety and effectiveness of ABT-874 administered weekly or every other week in patients with relapsing remitting and secondary progressive multiple sclerosis as compared to placebo. Effectiveness will be measured based on MRI scans done periodically throughout the study.

Detailed Description

This study was done in subjects with relapsing remitting MS or secondary progressive MS with the objective of assessing the safety and efficacy of 200 mg of ABT-874 weekly or QOW versus placebo. There were 3 phases to the study, 24 week double blind followed by 24 weeks of an active extension, followed by 48 weeks of double blind active extension. The trial was discontinued by Abbott in Aug 2006.

Conditions

Multiple Sclerosis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Blinding Strategy: TRIPLE

Study Groups

ABT-874 200 mg weekly

Group Type: EXPERIMENTAL

ABT-874/Human monoclonal antibody against IL-12

Intervention Type: DRUG

Placebo

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

ABT 874 QOW

Group Type: EXPERIMENTAL

ABT-874/Human monoclonal antibody against IL-12

Intervention Type: DRUG

Interventions

ABT-874/Human monoclonal antibody against IL-12

Intervention Type: DRUG

Placebo

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Age between 18 and 55 years
• Diagnosis of active relapse within 12 months of screening.
• At least one relapse within 12 months of screening.
• Must be able to walk at least 65 feet with or without assistance
• Off Copaxone or interferon therapy for two months prior to screening
• Able and willing to learn to self-administer weekly injections, or have a designee who will administer study medication
• Female participants must use contraceptives while on study drug

Exclusion Criteria

• Primary progressive multiple sclerosis (PPMS)
• Immunosuppressive therapy (such as azathioprine, methotrexate (MTX), but excluding corticosteroids) within six months of randomization. Subjects with previous treatment with cyclophosphamide, total lymphoid irradiation, mitoxantrone, cladribine, or bone marrow transplantation, regardless of duration, will be excluded from participation in this study
• Systemic corticosteroid therapy within four weeks prior to the first screening Magnetic Resonance Imaging (MRI)
• Participation in any clinical study, whether or not it involves an investigational drug within three months prior to the screening visit
• Use of any investigational drug with disease-modifying potential for the treatment of multiple sclerosis (MS) within six months of randomization (prior use of investigational agents for the symptomatic treatment of MS, e.g., 4-aminopyridine (4-AP), may be allowed following discussion with medical monitor
• Concomitant statin use in doses exceeding the manufacturers' maximum recommended daily dosages for treatment of hypercholesterolemia or as part of an MS disease-modifying protocol
• Infection or risk factors for severe infections
• Excessive immunosuppression or other factors associated with it, including human immunodeficiency virus (HIV) infection
• Severe, recurrent, or persistent infections [such as Hepatitis B or C, or borreliosis or recurrent urinary tract infection (UTI) (> 3 UTIs requiring antibiotic treatment per year) or recurrent pneumonia (> 2 pneumonias requiring antibiotic treatment per year) or infected decubitus ulcers]
• Evidence of current inactive tuberculosis (TB) infection; recent exposure to mycobacterium tuberculosis (converters to a positive purified protein derivative [PPD]). Subjects with a positive PPD or a chest X-ray suggestive of prior TB infection will be excluded
• Active tuberculosis disease
• Active chronic Lyme disease
• Active syphilis
• Any other significant infection requiring hospitalization or intravenous (IV) antibiotics in the month prior to Screening; or
• Infection requiring treatment with antibiotics in the two weeks prior to Screening.
• Any of the following risk factors for development of malignancy:

• History of lymphoma or leukemia
• Cutaneous squamous-cell or basal cell carcinoma (EXCEPT if treated more that two years prior to Screening with evidence of recurrence or residual disease)
• Other malignancy (EXCEPT if treated more than five years prior to Screening without evidence of recurrence or residual disease) or
• Disease associated with an increased risk of malignancy (such as familial polyposis).
• History of major immunologic reaction (such as serum sickness or anaphylactoid reaction) to an Immunoglobulin G (IgG) containing agent (such as intravenous (IV) gamma globulin, a fusion protein, or monoclonal antibody)
• Confounders of the assessment of neurologic response including other diseases that produce chronic neurologic manifestations (such as amyotrophic lateral sclerosis, Guillain-Barre syndrome, Lyme disease, myasthenia gravis, etc.)
• Prior exposure to anti-IL-12 antibodies
• Confounders of safety assessment, such as an unstable medical condition not related to MS (including those requiring an adjustment of treatment in the four weeks prior to Screening)
• Exacerbation of asthma requiring hospitalization in the ten years prior to Screening (subjects with asthma not requiring hospitalization should be discussed with the medical monitor prior to Screening)
• Pregnant or lactating females
• The following exclusionary laboratory values at screening or baseline:

• Hemoglobin (Hgb) <10 g/dL in females or <12 g/dL in males;
• White blood cell (WBC) count <3 x 109/L;
• Platelet count <100 x 109/L
• Serum aspartate transaminase (AST) or alanine transaminase (ALT) x 3 upper limits of normal (ULN);
• Serum total bilirubin >/= 3 mg/dL (>/= 51 x mol/L)
• Serum creatinine >1.6 mg/dL (> 141 x mol/L)
• Subject has a recent history of substance abuse or psychiatric illness that could preclude compliance with the protocol
• In the eight weeks prior to study drug administration, the subject has received a transfusion of any blood product, or has had 500 mL or more of blood removed by repetitive or one-time blood donation, plasmapheresis, or plasma exchange, or has lost 550 mL or more blood because of hemorrhage; or
• For any reason, subject is considered by the investigator to be an unsuitable candidate to receive ABT-874.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 60 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

AbbVie (prior sponsor, Abbott)

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Martin Kaul, MD

Role: STUDY_CHAIR

AbbVie

Locations

Site Reference ID/Investigator# 107

Phoenix, Arizona, United States

Site Reference ID/Investigator# 163

Sun City, Arizona, United States

Site Reference ID/Investigator# 156

Little Rock, Arkansas, United States

Site Reference ID/Investigator# 154

Irvine, California, United States

Site Reference ID/Investigator# 161

Laguna Hills, California, United States

Site Reference ID/Investigator# 84

Sacramento, California, United States

Site Reference ID/Investigator# 119

Boulder, Colorado, United States

Site Reference ID/Investigator# 111

Miami, Florida, United States

Site Reference ID/Investigator# 151

Tallahassee, Florida, United States

Site Reference ID/Investigator# 108

Atlanta, Georgia, United States

Site Reference ID/Investigator# 109

Atlanta, Georgia, United States

Site Reference ID/Investigator# 105

Northbrook, Illinois, United States

Site Reference ID/Investigator# 152

Indianapolis, Indiana, United States

Site Reference ID/Investigator# 258

Lenexa, Kansas, United States

Site Reference ID/Investigator# 261

Lexington, Kentucky, United States

Site Reference ID/Investigator# 116

Detroit, Michigan, United States

Site Reference ID/Investigator# 158

Traverse City, Michigan, United States

Site Reference ID/Investigator# 124

St Louis, Missouri, United States

Site Reference ID/Investigator# 259

Henderson, Nevada, United States

Site Reference ID/Investigator# 153

Lebanon, New Hampshire, United States

Site Reference ID/Investigator# 110

Albany, New York, United States

Site Reference ID/Investigator# 117

Charlotte, North Carolina, United States

Site Reference ID/Investigator# 113

Columbus, Ohio, United States

Site Reference ID/Investigator# 157

Dayton, Ohio, United States

Site Reference ID/Investigator# 114

Allentown, Pennsylvania, United States

Site Reference ID/Investigator# 128

Houston, Texas, United States

Site Reference ID/Investigator# 155

Bennington, Vermont, United States

Site Reference ID/Investigator# 132

Greenfield Park, , Canada

Site Reference ID/Investigator# 130

Halifax, , Canada

Site Reference ID/Investigator# 82

Ottawa, , Canada

Site Reference ID/Investigator# 169

Sherbrooke, , Canada

Site Reference ID/Investigator# 134

Vancouver, , Canada

Site Reference ID/Investigator# 149

Frankfurt, , Germany

Site Reference ID/Investigator# 137

Breda, , Netherlands

Site Reference ID/Investigator# 148

Nieuwegein, , Netherlands

Site Reference ID/Investigator# 138

Nijmwegen, , Netherlands

Site Reference ID/Investigator# 139

Sittard, , Netherlands

Site Reference ID/Investigator# 159

Liverpool, , United Kingdom

Site Reference ID/Investigator# 140

London, , United Kingdom

Site Reference ID/Investigator# 142

Newcastle upon Tyne, , United Kingdom

Site Reference ID/Investigator# 141

Nottingham, , United Kingdom

Site Reference ID/Investigator# 144

Oxford, , United Kingdom

Site Reference ID/Investigator# 143

Stoke-on-Trent, , United Kingdom

Site Reference ID/Investigator# 160

Whitechapel, , United Kingdom

Countries

United States; Canada; Germany; Netherlands; United Kingdom

References

Vollmer TL, Wynn DR, Alam MS, Valdes J. A phase 2, 24-week, randomized, placebo-controlled, double-blind study examining the efficacy and safety of an anti-interleukin-12 and -23 monoclonal antibody in patients with relapsing-remitting or secondary progressive multiple sclerosis. Mult Scler. 2011 Feb;17(2):181-91. doi: 10.1177/1352458510384496. Epub 2010 Dec 6.

Reference Type: DERIVED

PMID: 21135022 (View on PubMed)

Other Identifiers

M03-654

Identifier Type: -

Identifier Source: org_study_id